Absolute neutrophil count in peripheral blood predict prognosis in lung cancer patients treated with anlotinib

2021 ◽  
Author(s):  
Rong Chen ◽  
Fang Ying Lu ◽  
Min Zhou ◽  
Yi Guo
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Peripheral Blood ◽  
Lung Cancer Patients

scholarly journals Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib

2021 ◽  
Vol Volume 13 ◽  
pp. 3619-3627
Author(s):  
Rong Chen ◽  
Fang-Ying Lu ◽  
Bing Liu ◽  
Jingwen Huang ◽  
Min Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Peripheral Blood ◽  
Lung Cancer Patients

scholarly journals Absolute Neutrophil Count and Mean Platelet Volume in the Blood as Biomarkers to Detect Lung Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-5 ◽  
Author(s):  
Xuming Zhu ◽  
Yan Chen ◽  
Yubao Cui
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Mean Platelet Volume ◽  
Healthy Subjects ◽  
Healthy Individuals ◽  
Weak Correlation ◽  
Platelet Volume ◽  
Lung Cancer Patients

Objective. Inflammation plays an extremely considerable role in the development and progression of malignancies. Absolute neutrophil count (ANC) and mean platelet volume (MPV) in blood are associated with various inflammatory conditions and resulted in independent prognostic factors for lung cancer. However, whether ANC and MPV can be diagnostic markers for lung cancer remains unknown. This retrospective study investigated the roles of ANC and MPV, either alone or combined, in diagnosing lung cancer. Methods. This study analyzed data from lung cancer patients and healthy individuals in Wuxi People’s Hospital Affiliated with Nanjing Medical University. The Mann–Whitney U-test was performed to compare differences between lung cancer patients and healthy individuals. Spearman’s correlation analysis was used to assess correlations. Receiver operating characteristic (ROC) curves were performed to determine diagnostic accuracy. Results. 209 patients diagnosed with lung cancer and 236 healthy subjects were enrolled in this study. Levels of ANC and MPV increased in lung cancer patients compared with healthy individuals (P<0.001). ANC had statistically significant negative weak correlation with albumin concentrations (r=‐0.154, P=0.026), and MPV had statistically significant negative weak correlation with total protein concentrations (r=‐0.153, P=0.027) in lung cancer patients. ANC and neutrophil-to-lymphocyte ratio had statistically significant positive correlation in both lung cancer patients (r=0.756, P<0.001) and healthy subjects (r=0.639, P<0.001). MPV and platelet-to-lymphocyte ratio had statistically significant negative weak correlation in both lung cancer patients (r=‐0.242, P<0.001) and healthy subjects (r=‐0.325, P<0.001). ANC had sensitivity (SEN) and specificity (SPE) of 0.512 and 0.809, respectively, and the area under the curve (AUC) with 95% confidence interval (95% CI) was 0.656 (0.603-0.710). SEN and SPE of MPV were 0.928 and 0.708, respectively, and the AUC (95% CI) was 0.913 (0.889-0.938). When ANC and MPV were combined, SEN and SPE became 0.842 and 0.835, respectively, and the AUC (95% CI) became 0.919 (0.895-0.943). Conclusions. Compared with ANC or MPV alone, the combination of ANC and MPV can improve diagnostic ability to distinguish lung cancer patients from healthy subjects.

NLR and PLR ratios in prognostic assessment of non-small cell lung cancer patients

2016 ◽  
Vol 52 (1) ◽  
pp. 13-20
Author(s):  
Ewa Wójcik ◽  
Zofia Stasik ◽  
Urszula Rychlik ◽  
Jadwiga Tarapacz ◽  
Jan Kanty Kulpa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Platelet Count ◽  
Cancer Patients ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Reference Group ◽  
Performance Status ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

The aim of the present study was an assessment of NLR and PLR ratios and also C-reactive protein and hemoglobin concentrations prognostic values in non-small cell lung cancer patients (NSCLC). Studied group consisted of 95 NSCLC patients with different stages of disease. The reference group consisted of 57 healthy people and 10 with non-malignant lung lesions. For every investigated individual hematological parameters and CRP concentration were measured and also NLR and PLR ratios were calculated. Compared to the reference group, NSCLC cancer patients demonstrated significantly higher leukocyte count, absolute neutrophil count, platelet count, CRP concentration and significantly lower absolute lymphocyte count and hemoglobin concentration. The values of NLR and PLR in lung cancer patients were significantly higher than in the reference group. The area under ROC curve for CRP was significantly larger than for the rest of the studied parameters apart from NLR. The area under the ROC curve for NLR was significantly larger than for PLR. There were significant positive correlations between CRP and WBC (Rs=0.2887; P=0.0046), CRP vs. NLR (Rs=0.4127; P=0.0000), CRP vs. PLR (Rs=0.4009; P=0.0006), and also reciprocal correlation with hemoglobin (CRP vs. HGB Rs=-0.4753, P=0.0000). Univariate analysis confirmed dependencies between stage of disease, performance status, age, hemoglobin and CRP concentrations, leucocyte count, absolute neutrophil count, platelet count as also NLR and PLR values and probability of 5-year survival of patients. Multivariate analysis demonstrated, that apart from stage of disease and performance status, the independent prognostic factor in NSCLC was NLR higher than 2.5.

scholarly journals High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2966
Author(s):  
Dagmar Riemann ◽  
Wolfgang Schütte ◽  
Steffi Turzer ◽  
Barbara Seliger ◽  
Miriam Möller
Keyword(s):  
Lung Cancer ◽  
Dendritic Cells ◽  
Risk Factor ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Therapy Response ◽  
Inhibitor Therapy ◽  
Strong Positive Correlation ◽  
Blood Monocytes ◽  
Lung Cancer Patients

The aim of this study was to investigate the expression of the coinhibitory molecule PD-L1/CD274 in monocytes and dendritic cells (DC) in the blood of lung cancer patients undergoing PD1 inhibitor therapy and to correlate data with patient’s outcome. PD-L1/CD274 expression of monocytes, CD1c+ myeloid DC (mDC) and CD303+ plasmacytoid DC (pDC) was determined by flow cytometry in peripheral blood at immunotherapy onset. The predictive value of the PD-L1/CD274-expression data was determined by patients’ survival analysis. Patients with a high PD-L1/CD274 expression of monocytes and blood DC subpopulations rarely responded to PD1 inhibitor therapy. Low PD-L1/CD274 expression of monocytes and DC correlated with prolonged progression-free survival (PFS) as well as overall survival (OS). The highest PD-L1/CD274 expression was found in CD14+HLA-DR++CD16+ intermediate monocytes. Whereas the PD-L1/CD274 expression of monocytes and DC showed a strong positive correlation, only the PD-L1/CD274 expression of DC inversely correlated with DC amounts and lymphocyte counts in peripheral blood. Our results implicate that a high PD-L1/CD274 expression of blood monocytes and DC subtypes is a risk factor for therapy response and for the survival of lung cancer patients undergoing PD1 inhibitor therapy.

scholarly journals Lipid Accumulation in Peripheral Blood Dendritic Cells and Anticancer Immunity in Patients with Lung Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Ryo Arai ◽  
Sayo Soda ◽  
Tomoko Okutomi ◽  
Hiroko Morita ◽  
Fumito Ohmi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dendritic Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Lipid Accumulation ◽  
Stage Iii ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Treatment Naïve ◽  
Anticancer Immunity

We studied the subsets of peripheral blood dendritic cells (DCs) and lipid accumulation in DCs to investigate the involvement of DCs in the decreased anticancer immunity of advanced lung cancer patients. We analyzed the population of DC subsets in peripheral blood using flow cytometry. We then determined lipid accumulation in the DCs using BODIPY 650/665, a fluorophore with an affinity for lipids. Compared with healthy controls, the number of DCs in the peripheral blood of treatment-naive cancer patients was significantly reduced. In patients with stage III + IV disease, the numbers of myeloid DCs (mDCs) and plasmacytoid DCs were also significantly reduced. Lipid accumulation in DCs evaluated based on the fluorescence intensity of BODIPY 650/665 was significantly higher in stage III + IV lung cancer patients than in the controls. In the subset analysis, the fluorescence was highest for mDCs. The intracellularly accumulated lipids were identified as triglycerides. A decreased mixed leukocyte reaction was observed in the mDCs from lung cancer patients compared with those from controls. Taken together, the results show that lung cancer patients have a notably decreased number of peripheral blood DCs and their function as antigen-presenting cells is decreased due to their high intracellular lipid accumulation. Thereby, anticancer immunity is suppressed.

scholarly journals High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients

2017 ◽  
Vol 114 (10) ◽  
pp. 2544-2549 ◽  
Author(s):  
Yin Tang ◽  
Zhuo Wang ◽  
Ziming Li ◽  
Jungwoo Kim ◽  
Yuliang Deng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pleural Effusion ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Pleural Fluid ◽  
High Throughput ◽  
Targeted Therapies ◽  
Peripheral Blood ◽  
Detection Scheme ◽  
Lung Cancer Patients

Malignant pleural effusion (MPE), the presence of malignant cells in pleural fluid, is often the first sign of many cancers and occurs in patients with metastatic malignancies. Accurate detection of tumor cells in pleural fluid is crucial because the presence of MPE denotes an advanced stage of disease and directs a switch in clinical managements. Cytology, as a traditional diagnostic tool, has limited sensitivity especially when tumor cells are not abundant, and may be confounded by reactive mesothelial cells in the pleural fluid. We describe a highly sensitive approach for rapid detection of metabolically active tumor cells in MPE via exploiting the altered glucose metabolism of tumor cells relative to benign cells. Metabolically active tumor cells with high glucose uptake, as evaluated by a fluorescent glucose analog (2-NBDG), are identified by high-throughput fluorescence screening within a chip containing 200,000 addressable microwells and collected for malignancy confirmation via single-cell sequencing. We demonstrate the utility of this approach through analyzing MPE from a cohort of lung cancer patients. Most candidate tumor cells identified are confirmed to harbor the same driver oncogenes as their primary lesions. In some patients, emergence of secondary mutations that mediate acquired resistance to ongoing targeted therapies is also detected before resistance is manifested in the clinical imaging. The detection scheme can be extended to analyze peripheral blood samples. Our approach may serve as a valuable complement to cytology in MPE diagnosis, helping identify the driver oncogenes and resistance-leading mutations for targeted therapies.

Sign in / Sign up

Export Citation Format

Share Document